Ask about this productRelated genes to: ZNF418 antibody
- Gene:
- ZNF418 NIH gene
- Name:
- zinc finger protein 418
- Previous symbol:
- -
- Synonyms:
- KIAA1956, FLJ31551
- Chromosome:
- 19q13.43
- Locus Type:
- gene with protein product
- Date approved:
- 2003-03-17
- Date modifiied:
- 2015-09-29
Related products to: ZNF418 antibody
Related articles to: ZNF418 antibody
- Zinc-finger protein 418 (ZNF418) has been confirmed to be expressed in myocardial tissue. However, the role and mechanism of ZNF418 in pathological myocardial remodelling after myocardial infarction (MI) have not been reported. This study was to elucidate the effect and mechanism of ZNF418 on ventricular remodelling after MI in mice. - Source: PubMed
Publication date: 2024/05/07
Jiang HongfeiLai FeiWang XixingMeng FanqiZhu WeiliangHuang Shan - Head and neck squamous cell carcinoma (HNSCC) is one of the ten most common cancers. Most cancer cases originate from alcohol and tobacco consumption. However, studies have demonstrated that human papillomavirus () infection, particularly , may also significantly influence disease progression. The KRAB-ZNF family of genes is involved in epigenetic suppression, and its involvement in carcinogenesis is the subject of extensive studies. The available literature data demonstrate that they may play different roles, both as tumor suppressors and oncogenes. In this study, six ZNF genes, , , , , , and , were tested using several in silico approaches based on the TCGA and GEO datasets. Our analyses indicate that the expression of the analyzed ZNFs was significantly downregulated in tumor tissues and depended on tumor localization. The expression levels of ZNFs differed between -positive vs. -negative patients depending on the clinical-pathological parameters. More specifically, the patients with higher levels of and showed better survival rates than those with a lower expression. In addition, the level of expression in -positive () patients was higher than in -negative () patients ( < 0.0001) and was associated with better overall survival (OS). In conclusion, we demonstrate that expression highly correlates with infection, which renders a potential biomarker for HNSCC prognosis and treatment. - Source: PubMed
Publication date: 2022/12/16
Sobocińska JoannaNowakowska JoannaMolenda SaraOlechnowicz AnnaGuglas KacperKozłowska-Masłoń JoannaKazimierczak UrszulaMachnik MartaOleksiewicz UrszulaTeresiak AnnaLamperska KatarzynaKolenda Tomasz - Screening for candidate genes and genetic variants associated with litter size is important for goat breeding. The aim of this study was to analyze the relationship between single nucleotide polymorphisms (SNPs) in PPP2R5C and SLC39A5 and litter size in Yunshang black goats. KASP genotyping was used to detect the SNP genetic markers in the PPP2R5C and SLC39A5 in a population of 569 Yunshang black goats. The results show that there were two SNPs in the PPP2R5C and SLC39A5 promoter regions. Association analysis revealed that the polymorphisms PPP2R5C g.65977743C>T and SLC39A5 g.50676693T>C were significantly associated with the litter size of the third parity of Yunshang black goats (p < 0.05). To further explore the regulatory mechanism of the two genes, the expression of different genotypes of PPP2R5C and SLC39A5 was validated by RT-qPCR and Western blotting. The expression of PPP2R5C was significantly higher in individuals with the TT genotype than in those with the TC and CC genotypes (p < 0.05). The expression of SLC39A5 was also significantly higher in individuals with the TT genotype than in TC and CC genotypes (p < 0.05). Dual luciferase reporter analysis showed that the luciferase activity of PPP2R5C-C variant was significantly higher than that of PPP2R5C-T variant (p < 0.05). The luciferase activity of SLC39A5-T variant was significantly higher than that of SLC39A5-C variant (p < 0.05). Software was used to predict the binding of transcription factors to the polymorphic sites, and the results show that SOX18, ZNF418, and ZNF667 and NKX2-4 and TBX6 might bind to PPP2R5C g.65977743C>T and SLC39A5 g.50676693T>C, respectively. These results provide new insights into the identification of candidate genes for marker-assisted selection (MAS) in goats. - Source: PubMed
Publication date: 2022/10/17
Wang PengLi WentaoLiu ZiyiHe XiaoyunLan RongLiu YufangChu Mingxing - [This retracts the article DOI: 10.7150/ijbs.33658.]. - Source: PubMed
Publication date: 2022/06/07
Wang LiangSun LiankangWang YufengYao BowenLiu RunkunChen TianxiangTu KangshengLiu QingguangLiu Zhikui - Establishing epigenetic signature to improve the accuracy of survival prediction and optimize therapeutic strategies for laryngeal squamous cell carcinoma (LSCC) by a genome-wide integrated analysis of methylation and the transcriptome. LSCC DNA methylation datasets and RNA sequencing datasets were acquired from the Cancer Genome Atlas (TCGA). MethylMix was applied to detect DNA methylation-driven genes (MDGs), which developed an epigenetic signature. The predictive accuracy and clinical value of the epigenetic signature were evaluated by receiver operating characteristic and decision curve analysis, and compared with tumor-node-metastasis (TNM) stage system. In addition, prognostic value of the epigenetic signature was validated by external Gene Expression Omnibus (GEO) database. According to five MDGs of epigenetic signature, the candidate small molecules for LSCC were screen out by the CMap database. A total of 88 DNA MDGs were identified, five of which (MAGEB2, SUSD1, ZNF382, ZNF418, and ZNF732) were chosen to construct an epigenetic signature. The epigenetic signature can effectively divide patients into high-risk and low-risk group, with the area under curve (AUC) of 0.8 (5-year overall survival [OS]) and AUC of 0.745 (3-year OS). Stratification analysis affirmed that the epigenetic signature was still a significant statistical prognostic model in subsets of patients with different clinical variables. Multivariate Cox regression analysis indicated that the efficacy of epigenetic signature appears independent of other clinicopathological characteristics. In terms of predictive capacity and clinical usefulness, the epigenetic signature was superior to traditional TNM stage. In addition, the epigenetic signature was confirmed in external LSCC cohorts from GEO. Finally, CMap matched the 10 most significant small molecules as promising therapeutic drugs to reverse the LSCC gene expression. An epigenetic signature, with five DNA MDGs, was identified and validated in LSCC patients by integrating multidimensional genomic data, which may offer novel research directions and prospects for individualized treatment of patients with LSCC. - Source: PubMed
Publication date: 2021/01/21
Cui JieWang LipingZhong WaishengChen ZhenChen JieYang HongLiu Genglong